Onconova Therapeutics Inc (ONTX) 3.86 $ONTX
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 4.58 (-0.09), PCYC: 132.65 (-2.34), TGTX: 18.25 (+0.74), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), AZN: 71.80 (-1.80), ABBV: 65.27 (-1.76), INFI: 17.78 (-0.21), CELGZ: 3.51 (-0.03), NVS: 93.52 (-0.82)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 1.80 (-0.10), GILD: 104.13 (-0.18), GERN: 3.24 (+0.01), ONTX: 3.86 (-0.06), CTIC: 2.40 (+0.02), BMY: 58.75 (-0.93), STML: 16.50 (+0.31), NVS: 93.52 (-0.82), MEIP: 4.20 (unch), CELGZ: 3.51 (-0.03), XLRN: 41.77 (+0.29)
Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 74.65 (-1.27), AZN: 71.80 (-1.80), AMGN: 164.53 (-1.55), ONTX: 3.86 (-0.06), GSK: 42.42 (-0.93), STML: 16.50 (+0.31)
Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 6:45PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) at the 56 American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.
ONTX: 3.86 (-0.06)
Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 11:01AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) and non-proliferative acute myeloid leukemia (AML) at the 56 American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.
ONTX: 3.86 (-0.06)
Onconova to host investor event
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 8:22AM CST
ONTX: 3.86 (-0.06)
Onconova Therapeutics to Host Analyst Event in New York City on December 12, 2014
GlobeNewswire - Fri Dec 05, 8:00AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, will be hosting an investor and analyst event on Friday December 12, 2014 from 8:30 am to 12:00 pm ET in New York, NY. The program will focus on recent progress and advances with rigosertib for the treatment of patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML). The event will feature presentations by leading experts in the fields of oncology and hematology and Onconova management.
ONTX: 3.86 (-0.06)
Onconova Therapeutics beats by $0.06
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:37PM CST
ONTX: 3.86 (-0.06)
Onconova Therapeutics, Inc. Reports Third Quarter 2014 Financial and Operational Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ONTX: 3.86 (-0.06)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.57 (+0.01), IMGN: 10.01 (unch), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), OXGN: 1.71 (-0.11), XLRN: 41.77 (+0.29), KPTI: 34.85 (+1.35), NVS: 93.52 (-0.82)
Onconova Announces Ten Presentations at the 2014 ASH Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
--Phase 3 ONTIME Trial Data Selected for Oral Presentation--
ONTX: 3.86 (-0.06)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.95 (-0.70), INCY: 74.65 (-1.27), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), STML: 16.50 (+0.31), SNTA: 2.87 (+0.04), KBIO: 1.80 (-0.10), BPTH: 2.67 (+0.03), CELGZ: 3.51 (-0.03), NVS: 93.52 (-0.82)
Merrimack Does Well to License Marginal Cancer Drug to Baxter
at The Street - Wed Sep 24, 7:14AM CDT
Baxter has a hunger for cancer drugs with hair.
MACK: 10.64 (+0.42), BAX: 71.77 (-1.34), ONTX: 3.86 (-0.06), CTIC: 2.40 (+0.02)
Global Essential Thrombocythemia Therapeutics Pipeline Review 2014 - 10 Drug Profiles from 9 Companies
M2 - Thu Sep 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fshlvt/essential) has announced the addition of the "Essential Thrombocythemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Shire Plc - Incyte Corporation - Galena Biopharma, Inc. - Italfarmaco S.p.A. - Promedior, Inc. - Onconova Therapeutics, Inc. - Pharma Mar, S.A. Drug Profiles - anagrelide hydrochloride - ruxolitinib phosphate - PRM-151 - plitidepsin - givinostat - gandotinib - anagrelide hydrochloride CR - AZD-1480 - rigosertib sodium - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fshlvt/essential
SHPG: 213.70 (-0.41), INCY: 74.65 (-1.27), AZN: 71.80 (-1.80), ONTX: 3.86 (-0.06), GALE: 1.69 (unch), LLY: 69.55 (-2.06)
Onconova Therapeutics, Inc. to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 6:01AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and CEO, will present at the Rodman & Renshaw 16 Annual Global Investment Conference in New York, NY. The presentation will take place on Wednesday, September 10 at 2:05 p.m. ET.
ONTX: 3.86 (-0.06)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Aug 15, 9:08AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
FCEL: 1.62 (+0.03), COT: 6.45 (-0.09), NVAX: 5.76 (-0.17), ONTX: 3.86 (-0.06), SQNS: 1.27 (+0.02)
Onconova Therapeutics, Inc. Reports Second Quarter 2014 Financial and Operational Results
GlobeNewswire - Wed Aug 13, 3:01PM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the second quarter ended June 30, 2014.
ONTX: 3.86 (-0.06)
Onconova Therapeutics, Inc. Announces Timing for Second Quarter 2014 Financial Results and Conference Call
GlobeNewswire - Wed Aug 06, 7:57AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that financial results for the Company's second quarter ended June 30, 2014 will be released on Wednesday, August 13, 2014. The Company will host a conference call and audio webcast at 4:30 PM ET on the same day.
ONTX: 3.86 (-0.06)
4 Under-$10 Stocks to Trade for Breakouts
at The Street - Wed Aug 06, 7:18AM CDT
These stocks under $10 are within range of triggering breakout trades.
IDRA: 3.84 (-0.03), ONTX: 3.86 (-0.06), HIMX: 7.97 (-0.02)
5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Jun 26, 12:56PM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
HEAR: 3.82 (+0.22), NWBO: 4.98 (+0.04), KBIO: 1.80 (-0.10), SFUN: 7.73 (+0.06), ONTX: 3.86 (-0.06), PRAN: 1.86 (-0.05)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 4.58 (-0.09), PCYC: 132.65 (-2.34), TGTX: 18.25 (+0.74), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), AZN: 71.80 (-1.80), ABBV: 65.27 (-1.76), INFI: 17.78 (-0.21), CELGZ: 3.51 (-0.03), NVS: 93.52 (-0.82)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 1.80 (-0.10), GILD: 104.13 (-0.18), GERN: 3.24 (+0.01), ONTX: 3.86 (-0.06), CTIC: 2.40 (+0.02), BMY: 58.75 (-0.93), STML: 16.50 (+0.31), NVS: 93.52 (-0.82), MEIP: 4.20 (unch), CELGZ: 3.51 (-0.03), XLRN: 41.77 (+0.29)
Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 74.65 (-1.27), AZN: 71.80 (-1.80), AMGN: 164.53 (-1.55), ONTX: 3.86 (-0.06), GSK: 42.42 (-0.93), STML: 16.50 (+0.31)
Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 6:45PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) at the 56 American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.
ONTX: 3.86 (-0.06)
Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 11:01AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) and non-proliferative acute myeloid leukemia (AML) at the 56 American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.
ONTX: 3.86 (-0.06)
Onconova to host investor event
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 8:22AM CST
ONTX: 3.86 (-0.06)
Onconova Therapeutics to Host Analyst Event in New York City on December 12, 2014
GlobeNewswire - Fri Dec 05, 8:00AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, will be hosting an investor and analyst event on Friday December 12, 2014 from 8:30 am to 12:00 pm ET in New York, NY. The program will focus on recent progress and advances with rigosertib for the treatment of patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML). The event will feature presentations by leading experts in the fields of oncology and hematology and Onconova management.
ONTX: 3.86 (-0.06)
Onconova Therapeutics beats by $0.06
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:37PM CST
ONTX: 3.86 (-0.06)
Onconova Therapeutics, Inc. Reports Third Quarter 2014 Financial and Operational Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ONTX: 3.86 (-0.06)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.57 (+0.01), IMGN: 10.01 (unch), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), OXGN: 1.71 (-0.11), XLRN: 41.77 (+0.29), KPTI: 34.85 (+1.35), NVS: 93.52 (-0.82)
Onconova Announces Ten Presentations at the 2014 ASH Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
--Phase 3 ONTIME Trial Data Selected for Oral Presentation--
ONTX: 3.86 (-0.06)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.95 (-0.70), INCY: 74.65 (-1.27), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), STML: 16.50 (+0.31), SNTA: 2.87 (+0.04), KBIO: 1.80 (-0.10), BPTH: 2.67 (+0.03), CELGZ: 3.51 (-0.03), NVS: 93.52 (-0.82)
Merrimack Does Well to License Marginal Cancer Drug to Baxter
at The Street - Wed Sep 24, 7:14AM CDT
Baxter has a hunger for cancer drugs with hair.
MACK: 10.64 (+0.42), BAX: 71.77 (-1.34), ONTX: 3.86 (-0.06), CTIC: 2.40 (+0.02)
Global Essential Thrombocythemia Therapeutics Pipeline Review 2014 - 10 Drug Profiles from 9 Companies
M2 - Thu Sep 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fshlvt/essential) has announced the addition of the "Essential Thrombocythemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Shire Plc - Incyte Corporation - Galena Biopharma, Inc. - Italfarmaco S.p.A. - Promedior, Inc. - Onconova Therapeutics, Inc. - Pharma Mar, S.A. Drug Profiles - anagrelide hydrochloride - ruxolitinib phosphate - PRM-151 - plitidepsin - givinostat - gandotinib - anagrelide hydrochloride CR - AZD-1480 - rigosertib sodium - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fshlvt/essential
SHPG: 213.70 (-0.41), INCY: 74.65 (-1.27), AZN: 71.80 (-1.80), ONTX: 3.86 (-0.06), GALE: 1.69 (unch), LLY: 69.55 (-2.06)
Onconova Therapeutics, Inc. to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 6:01AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and CEO, will present at the Rodman & Renshaw 16 Annual Global Investment Conference in New York, NY. The presentation will take place on Wednesday, September 10 at 2:05 p.m. ET.
ONTX: 3.86 (-0.06)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Aug 15, 9:08AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
FCEL: 1.62 (+0.03), COT: 6.45 (-0.09), NVAX: 5.76 (-0.17), ONTX: 3.86 (-0.06), SQNS: 1.27 (+0.02)
Onconova Therapeutics, Inc. Reports Second Quarter 2014 Financial and Operational Results
GlobeNewswire - Wed Aug 13, 3:01PM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the second quarter ended June 30, 2014.
ONTX: 3.86 (-0.06)
Onconova Therapeutics, Inc. Announces Timing for Second Quarter 2014 Financial Results and Conference Call
GlobeNewswire - Wed Aug 06, 7:57AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that financial results for the Company's second quarter ended June 30, 2014 will be released on Wednesday, August 13, 2014. The Company will host a conference call and audio webcast at 4:30 PM ET on the same day.
ONTX: 3.86 (-0.06)
4 Under-$10 Stocks to Trade for Breakouts
at The Street - Wed Aug 06, 7:18AM CDT
These stocks under $10 are within range of triggering breakout trades.
IDRA: 3.84 (-0.03), ONTX: 3.86 (-0.06), HIMX: 7.97 (-0.02)
5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Jun 26, 12:56PM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
HEAR: 3.82 (+0.22), NWBO: 4.98 (+0.04), KBIO: 1.80 (-0.10), SFUN: 7.73 (+0.06), ONTX: 3.86 (-0.06), PRAN: 1.86 (-0.05)
